The companies will screen targets identified by Second Genome’s microbiome discovery platform and Evotec’s drug discovery platform and chemical libraries to yield drug molecules for clinial development. Their initial focus will be treatment of inflammatory conditions of the gut. For more information, read the Pharmaceutical Business Review report.